[go: up one dir, main page]

HK1165413A1 - -異丙苯基山梨醇化合物作為 抑制劑 - Google Patents

-異丙苯基山梨醇化合物作為 抑制劑

Info

Publication number
HK1165413A1
HK1165413A1 HK12105940.6A HK12105940A HK1165413A1 HK 1165413 A1 HK1165413 A1 HK 1165413A1 HK 12105940 A HK12105940 A HK 12105940A HK 1165413 A1 HK1165413 A1 HK 1165413A1
Authority
HK
Hong Kong
Prior art keywords
sglt1
inhibitors
glucitol compounds
isopropylphenyl glucitol
isopropylphenyl
Prior art date
Application number
HK12105940.6A
Other languages
English (en)
Inventor
柿沼浩行
小橋陽平
長南具通
大井隆宏
鹽澤史康
岩田由紀
川部憲
Original Assignee
大正制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大正制藥株式會社 filed Critical 大正制藥株式會社
Publication of HK1165413A1 publication Critical patent/HK1165413A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
HK12105940.6A 2009-02-23 2012-06-18 -異丙苯基山梨醇化合物作為 抑制劑 HK1165413A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009038776 2009-02-23
PCT/JP2010/053187 WO2010095768A1 (en) 2009-02-23 2010-02-23 4 -isopropylphenyl glucitol compounds as sgltl inhibitors

Publications (1)

Publication Number Publication Date
HK1165413A1 true HK1165413A1 (zh) 2012-10-05

Family

ID=42101407

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105940.6A HK1165413A1 (zh) 2009-02-23 2012-06-18 -異丙苯基山梨醇化合物作為 抑制劑

Country Status (22)

Country Link
US (1) US8466113B2 (zh)
EP (1) EP2398786B1 (zh)
JP (1) JP5505741B2 (zh)
KR (1) KR101653853B1 (zh)
CN (1) CN102414191B (zh)
AR (1) AR075582A1 (zh)
AU (1) AU2010216634B2 (zh)
BR (1) BRPI1008653A2 (zh)
CA (1) CA2752212C (zh)
CL (1) CL2011002041A1 (zh)
CO (1) CO6362001A2 (zh)
ES (1) ES2397086T3 (zh)
HK (1) HK1165413A1 (zh)
IL (1) IL214727A0 (zh)
MX (1) MX2011008839A (zh)
MY (1) MY155658A (zh)
PE (1) PE20120648A1 (zh)
RU (1) RU2518896C2 (zh)
SG (1) SG173801A1 (zh)
TW (1) TWI460187B (zh)
WO (1) WO2010095768A1 (zh)
ZA (1) ZA201105928B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656092B2 (ja) * 2010-08-20 2015-01-21 大正製薬株式会社 ４−イソプロピルフェニルグルシトール化合物の結晶形及びその製造方法
ES2546253T3 (es) 2010-08-20 2015-09-22 Taisho Pharmaceutical Co., Ltd. Compuesto 4-isopropil-6-metoxifenilglucitol
JP5817317B2 (ja) * 2010-08-20 2015-11-18 大正製薬株式会社 ４−イソプロピルフェニルグルシトール化合物を有効成分として含有することを特徴とする糖尿病の予防又は治療剤
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
KR102078433B1 (ko) * 2013-02-04 2020-02-17 다이쇼 세이야꾸 가부시끼가이샤 변비증의 예방 또는 치료약
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
JP2019142774A (ja) * 2016-06-20 2019-08-29 大正製薬株式会社 腸内環境改善剤
CN110066302B (zh) * 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
EP3747892A4 (en) * 2018-01-31 2021-11-03 Sunshine Lake Pharma Co., Ltd. GLUCOPYRANOSYL DERIVATIVE AND USE OF IT
CN110117300A (zh) * 2018-04-23 2019-08-13 中国科学院成都生物研究所 包含钠-葡萄糖协同转运蛋白1抑制剂的药物用途
CN108610385A (zh) * 2018-04-23 2018-10-02 中国科学院成都生物研究所 一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途
US12258367B2 (en) * 2019-03-29 2025-03-25 Medshine Discovery Inc. Glucoside derivative that acts as SGLT1 inhibitor and application thereof
WO2021004498A1 (en) * 2019-07-10 2021-01-14 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses
WO2021227441A1 (zh) * 2020-05-15 2021-11-18 上海喆邺生物科技有限公司 芳基葡糖苷衍生物及其在药物中的用途
US20230365610A1 (en) * 2020-05-15 2023-11-16 Shanghai Zheye Biotechnology Co. Ltd. Aryl Glucoside Derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1400529A4 (en) 2001-05-30 2007-12-19 Kissei Pharmaceutical GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
AU2003254847B2 (en) 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
AU2003289156A1 (en) 2002-12-04 2004-06-23 Kissei Pharmaceutical Co., Ltd. Preventive or remedy for diseases caused by hyperglycemia
ES2363941T3 (es) * 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
JP2009167104A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
CA2652707A1 (en) 2006-05-19 2007-11-29 Taisho Pharmaceutical Co., Ltd. C-phenyl glycitol compound

Also Published As

Publication number Publication date
WO2010095768A1 (en) 2010-08-26
CA2752212A1 (en) 2010-08-26
CN102414191B (zh) 2014-04-16
EP2398786A1 (en) 2011-12-28
CO6362001A2 (es) 2012-01-20
CL2011002041A1 (es) 2012-04-09
KR101653853B1 (ko) 2016-09-02
RU2518896C2 (ru) 2014-06-10
EP2398786B1 (en) 2012-12-12
BRPI1008653A2 (pt) 2016-03-08
AU2010216634A1 (en) 2011-09-22
TW201040195A (en) 2010-11-16
ES2397086T3 (es) 2013-03-04
AU2010216634B2 (en) 2014-07-10
JP2012518631A (ja) 2012-08-16
SG173801A1 (en) 2011-09-29
US8466113B2 (en) 2013-06-18
MY155658A (en) 2015-11-13
CN102414191A (zh) 2012-04-11
JP5505741B2 (ja) 2014-05-28
TWI460187B (zh) 2014-11-11
MX2011008839A (es) 2011-09-28
AR075582A1 (es) 2011-04-20
IL214727A0 (en) 2011-11-30
US20110306759A1 (en) 2011-12-15
KR20110121626A (ko) 2011-11-07
PE20120648A1 (es) 2012-05-31
RU2011138962A (ru) 2013-03-27
WO2010095768A8 (en) 2011-08-04
CA2752212C (en) 2016-08-16
ZA201105928B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
HK1165413A1 (zh) -異丙苯基山梨醇化合物作為 抑制劑
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
HUS1700026I1 (hu) Tetraciklusos vegyület
IL238338A0 (en) Processes for preparing sglt2 inhibitors
EP2463280A4 (en) CHROME COMPOUND
PL2393812T3 (pl) Podstawione spiroamidy jako modulatory B1R
IL219916A0 (en) Imidazopyridine derivatives as jak inhibitor
HK1170241A1 (zh) 可用作 的抑制劑的化合物的製備方法
ZA201107772B (en) Substituted spiro-amide compounds
HK1156306A1 (zh) 作為 -脯氨酰基- -羥化酶抑制劑的取代的二氫吡唑啉酮類化合物
EP2444401A4 (en) NEW IMIDAZOPYRIDINE COMPOUND
GB0915927D0 (en) Novel inhibitors
GB0914441D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy
GB0901497D0 (en) Compound for therapy
GB0907825D0 (en) Novel compound

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230221